Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Recommendation of “Moderate Buy” from Analysts

Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Rating) has received a consensus recommendation of “Moderate Buy” from the seven research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $32.00.

Several brokerages have recently issued reports on ACRS. BTIG Research reduced their price target on shares of Aclaris Therapeutics from $32.00 to $29.00 and set a “buy” rating for the company in a report on Tuesday, March 7th. Cantor Fitzgerald restated an “overweight” rating and set a $38.00 price objective on shares of Aclaris Therapeutics in a research note on Tuesday, February 7th. HC Wainwright cut their price objective on shares of Aclaris Therapeutics from $50.00 to $43.00 and set a “buy” rating on the stock in a research note on Tuesday, March 7th. StockNews.com started coverage on shares of Aclaris Therapeutics in a research note on Thursday, May 18th. They set a “sell” rating on the stock. Finally, The Goldman Sachs Group cut their price objective on shares of Aclaris Therapeutics from $25.00 to $21.00 and set a “buy” rating on the stock in a research note on Tuesday, March 7th.

Aclaris Therapeutics Price Performance

Aclaris Therapeutics stock opened at $8.33 on Friday. The company has a market cap of $588.76 million, a PE ratio of -5.78 and a beta of 0.51. The company has a fifty day moving average price of $8.59 and a two-hundred day moving average price of $12.67. Aclaris Therapeutics has a 12 month low of $5.77 and a 12 month high of $18.96.

Aclaris Therapeutics (NASDAQ:ACRS – Get Rating) last announced its quarterly earnings results on Monday, May 8th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.02. Aclaris Therapeutics had a negative net margin of 312.32% and a negative return on equity of 46.40%. The company had revenue of $2.50 million during the quarter, compared to the consensus estimate of $1.75 million. During the same quarter in the previous year, the company posted ($0.31) earnings per share. The company’s revenue for the quarter was up 66.7% compared to the same quarter last year. Equities research analysts anticipate that Aclaris Therapeutics will post -1.81 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Douglas J. Manion acquired 6,500 shares of the business’s stock in a transaction on Thursday, March 9th. The shares were purchased at an average price of $7.74 per share, for a total transaction of $50,310.00. Following the acquisition, the chief executive officer now owns 6,500 shares in the company, valued at $50,310. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Aclaris Therapeutics news, insider Joseph Monahan sold 14,800 shares of Aclaris Therapeutics stock in a transaction dated Thursday, March 2nd. The stock was sold at an average price of $12.37, for a total transaction of $183,076.00. Following the transaction, the insider now owns 151,261 shares of the company’s stock, valued at approximately $1,871,098.57. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Douglas J. Manion bought 6,500 shares of the stock in a transaction on Thursday, March 9th. The shares were acquired at an average cost of $7.74 per share, for a total transaction of $50,310.00. Following the purchase, the chief executive officer now owns 6,500 shares in the company, valued at $50,310. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 44,800 shares of company stock worth $554,096. 6.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Aclaris Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Great West Life Assurance Co. Can purchased a new position in Aclaris Therapeutics during the 3rd quarter valued at about $31,000. UBS Group AG grew its stake in shares of Aclaris Therapeutics by 41.4% in the 2nd quarter. UBS Group AG now owns 2,406 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 704 shares in the last quarter. Point72 Middle East FZE bought a new stake in shares of Aclaris Therapeutics in the 4th quarter valued at approximately $75,000. Corton Capital Inc. bought a new stake in shares of Aclaris Therapeutics in the 1st quarter valued at approximately $84,000. Finally, State of Wyoming bought a new stake in shares of Aclaris Therapeutics in the 4th quarter valued at approximately $87,000. Hedge funds and other institutional investors own 95.33% of the company’s stock.

About Aclaris Therapeutics

(Get Rating)

Aclaris Therapeutics, Inc operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments.